HysensBio Co., Ltd.
π°π·South Korea
- Country
- π°π·South Korea
- Ownership
- Holding
- Established
- 2016-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.hysensbio.com
Clinical Trials
3
Active:0
Completed:2
Trial Phases
2 Phases
Phase 1:1
Phase 2:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)β’ Click on a phase to view related trials
Phase 2
2 (66.7%)Phase 1
1 (33.3%)Phase 2 Study of KH001 in Long-term Relief from Dentin Hypersensitivity
- First Posted Date
- 2024-06-18
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- HysensBio Co., Ltd
- Target Recruit Count
- 120
- Registration Number
- NCT06464939
- Locations
- πΊπΈ
Forsyth Institute, Cambridge, Massachusetts, United States
πΊπΈADA Forsyth, Cambridge, Massachusetts, United States
A Study to Evaluate the Efficacy and Safety of KH001 in Patients with Dentin Hypersensitivity
- First Posted Date
- 2024-02-20
- Last Posted Date
- 2025-03-14
- Lead Sponsor
- HysensBio Co., Ltd
- Target Recruit Count
- 171
- Registration Number
- NCT06264453
- Locations
- π°π·
Kyung Hee University Dental Hospital, Seoul, Korea, Republic of
Evaluation of the Safety and Tolerability of KH001 in Dentin Hypersensitivity Patients
- First Posted Date
- 2021-03-18
- Last Posted Date
- 2025-02-26
- Lead Sponsor
- HysensBio Co., Ltd
- Target Recruit Count
- 40
- Registration Number
- NCT04804514
- Locations
- π°π·
Seoul National University Dental Hospital, Seoul, Korea, Republic of
News
No news found